Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.

Bunte K, Beikler T. · 2019

Read Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. by Bunte K, Beikler T. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6679067.txt.

Introduction

Bunte and Beikler review Th17 cells and the IL-23/IL-17 axis in periodontitis and kin diseases. Their review appears in the International Journal of Molecular Sciences. Innate and adaptive immunity normally act in tight balance. When that balance breaks, chronic inflammation and autoimmunity follow. Th17 cells and their cytokine IL-17 sit at the centre. IL-23 keeps their harmful activity going. The axis features in psoriasis and rheumatoid arthritis. Inflammatory bowel disease shares the same wiring.

Periodontitis links to these body-wide conditions. A skewed oral microbiome starts the gum inflammation. Left alone, it destroys attachment and jaw bone. The review traces Th17 cell growth step by step. It then maps shared illness patterns across diseases. Drugs that tune the axis close the survey.

Catalog record

CREATORBunte K, Beikler T.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE93 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6679067

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases By Kübra Bunte, Thomas Beikler Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms20143394 ABSTRACT Innate immunity represents the semi-specific first line of defense and provides the initial host response to tissue injury, trauma, and pathogens. Innate immunity activates the adaptive immunity, and both act highly regulated together to establish and maintain tissue homeostasis. Any dysregulation of this interaction can result in chronic inflammation and autoimmunity and is thought to be a major underlying cause in the initiation and progression of highly prevalent immune-mediated inflammatory diseases (IMIDs) such as psoriasis, rheumatoid arthritis, inflammatory bowel diseases among others, and periodontitis. Th1 and Th2 cells of the adaptive immune system are the major players in the pathogenesis of IMIDs. In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an overview of the current knowledge about the differentiation of Th17 cells and the role of the IL-17/IL-23 axis in the pathogenesis of IMIDs. Moreover, it aims to review the association of these IMIDs with periodontitis and briefly discusses the therapeutic potential of agents that modulate the IL-17/IL-23 axis. 1. INTRODUCTION Innate immunity represents the semi-specific first line of defense for all primitive and complex multicellular organisms and provides the initial acute inflammatory reaction to tissue injury, trauma, or pathogens [1]. Innate immunity is a rather unspecific and immediate reaction that recruits immune cells to the injury or infection site through various cytokines (e.g., prostaglandins, tumor necrosis factor (TNF), interleukin (IL)-1β, and others). Moreover, it promotes phagocytosis, and activates the complement and adaptive immune system [2]. In contrast to the innate immune system, the activation of the adaptive immune system results in an antigen specific host response that is mediated by T and B cells. It usually requires more time than the innate immune system to react since it turns progenitor cells into regulatory and effector cells with distinct functions, such as (i) self and non-self-antigen recognition, (ii) enhanced elimination of pathogens or infected cells, and (iii) development of immune memory [3]. The innate and adaptive immunity interaction represents a complex system. They are equally required to establish and maintain health and tissue homeostasis and both comprise cellular and humoral immunity components. Humoral immunity refers to antigen-specific antibody production to neutralize toxins and pathogens, mediation of allergic reactions and autoimmunity, generation of immune memory cells, and stimulation of cytokine secretion; whereas, cellular immunity eradicates pathogens by macrophages or natural killer cells, eliminates intracellular bacteria via induction of cytotoxic T-cell-mediated apoptosis, and stimulates tissue cells, such as fibroblasts, to secrete cytokines that further modulate innate and adaptive immune system responses [4]. The inflammation triggered by pathogens, tissue injury, or trauma is typically self-limiting and results in tissue repair and reestablishment of tissue homeostasis following elimination of the cause. However, an alteration of the regular immune response may result in persistence of the acute inflammation, its transition into chronic inflammation, and could even induce autoimmune reactions in susceptible individuals. This altered inflammatory response is believed to be a major underlying cause in the initiation and progression of disorders, such as immune-mediated inflammatory diseases (IMIDs) [5]. IMIDs are the definition of a group of seemingly unrelated diseases that share common inflammatory pathways and are triggered by or result in the dysregulation of innate and adaptive immune system functions [6]. The definitive etiology is still unclear; however, genetic susceptibility and environmental factors such as infection and trauma may initiate these conditions, that include, but are not limited to, psoriasis, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, Sjögren syndrome, and type 1 diabetes [7,8]. Any organ system may be inflicted, and individuals may encounter a considerable reduction in quality of life, significant morbidity, and reduced lifespan [6]. Initiated and perpetuated by a dysbiotic oral microbiome, periodontitis is the most common inflammatory disease of tooth supporting tissues, with a high prevalence of up to 70% among the world’s dentate adults [9,10]. The host immune and inflammatory responses disrupted by a dysbiotic microbiome are considered to be the main cause for the initiation, establishment, and progression of periodontal inflammation and tissue breakdown [11]. If left untreated, periodontitis results in progressive periodontal attachment and alveolar bone loss, which subsequently results in tooth loss. Co-existence of an IMID with another systemic inflammatory/autoimmune disease or periodontitis is not uncommon, e.g., 20–30% of patients with psoriasis will eventually develop psoriatic arthritis (PsA) [12]. Although the pathogenesis of IMIDs is not yet entirely understood and elucidated and a causative bidirectional relationship between IMIDs and periodontitis has not been proven yet, the comorbidities indicate the involvement of a dysbalanced inflammatory cytokine network in the disease processes [13,14,15]. As mentioned before, cytokines and antigen presentation attract and activate adaptive immune system cells. In this regard, CD4+ helper T cells are pivotal players [16]. CD4+ helper T cells differentiate into regulatory and effector T cell subsets i.e., Th1, Th2, Th17, follicular helper T (Tfh) cells, and regulatory T cells (Tregs), following activation. Until the discovery of other cell lineages, Th1 and Th2 were thought to be the only cells differentiating from progenitor CD4+ helper T cells [17]. In this classical Th1/Th2 paradigm, Th1 cells mainly produce interleukin(IL)-2 and interferon gamma (IFN-γ) and are involved in cellular immunity [18]. Th2 cells are mainly responsible for humoral immunity via the activation of B cells, mast cells, and production of immunoglobulin E, and primarily produce IL-4, IL-5, and IL-13 [19]. The first findings that indicated the existence of a novel effector population of CD4+ helper T cells were provided by an animal model of multiple sclerosis (experimental autoimmune encephalitis, EAE) [20]. According to the Th1/Th2 paradigm, it was initially hypothesized that IL-12 and, hence, Th1 cells and IFNγ were playing the central role in this inflammatory disease; however, it was demonstrated that functional Th1 pathways downregulate the onset and progression of EAE in IFNγ- and IL-12-deficient mice [21,22,23]. Later it was demonstrated that indeed IL-23, and not IL-12, was involved in the EAE pathogenesis [24]. This was further substantiated when the transfer of IL-17 producing T cells to healthy mice was sufficient to induce EAE [25]. In addition, IL-23-deficient animals were shown to be unable to recruit IL-17 producing T cells [26]. These and other studies led to the identification of a novel CD4+ helper T cell subset named T helper 17 (Th17) cell lineage that was characterized by IL-17 production, a cytokine that Th1 and Th2 are not able to produce [17,27]. The Th1/Th2 paradigm provided a framework for understanding the pathogenesis of several conditions, such as psoriasis, rheumatoid arthritis, inflammatory bowel diseases, and periodontitis. However, the identification of Th17 cells as a distinct lineage of CD4+ helper T cells has greatly expanded the understanding of autoimmunity and inflammation and filled in some of the missing gaps in host immunity that could not be fully explained by the Th1/Th2. Although there is still much to be elucidated, this review aims to provide an overview of the current knowledge about the Th17 cell lineage, the role of its key cytokine IL-17, the IL-17/IL-23 axis in health and disease, and strategies that target IL-17 related pathways.

Read the complete text